Rockwell Medical (RMTI) Stock Price, News & Analysis

Company Overview

Rockwell Medical, Inc. is a specialty pharmaceutical company focused on therapies for chronic kidney disease and related disorders. The company’s primary product, Triferic™ (ferric pyrophosphate citrate), is designed to maintain iron balance in hemodialysis patients by replacing iron losses directly through the dialysis process. In addition, Rockwell Medical markets Calcitriol Injection, an active form of vitamin D indicated for patients with chronic renal failure. These products target key supportive care needs in the nephrology market.

Founded in 1992 and headquartered in Wixom, Michigan, Rockwell Medical has built its business through research, development and strategic licensing partnerships. The company obtained FDA approval for Triferic in 2015 and subsequently secured reimbursement coverage with major U.S. dialysis providers. In parallel, Rockwell Medical has entered into licensing and distribution agreements across Europe and other regions, enabling access to its therapies through select international partners.

Over its history, Rockwell Medical has evolved its product portfolio via both internal innovation and select divestitures. For example, the company previously marketed Feraheme® for iron deficiency anemia in adults but divested that asset to concentrate on its core nephrology pipeline. Today, Rockwell Medical’s pipeline continues to advance next-generation formulations aimed at improving patient outcomes and reducing treatment burden for those with chronic kidney disease.

Rockwell Medical is led by an experienced management team with deep expertise in renal care and pharmaceutical commercialization. The company’s executive leadership drives both clinical development and commercial strategy, working closely with dialysis providers, physicians and regulatory authorities to expand the availability of its therapies. Through ongoing research and global partnerships, Rockwell Medical remains committed to delivering novel solutions for patients undergoing dialysis.

Key Stats

• Today's Range: $1.25 to $1.42
• 50-Day Range: $0.79 to $1.23
• 52-Week Range: $0.78 to $5.15
• Volume: 1.82 million shs
• Average Volume: 437,912 shs
• Market Capitalization: $44.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Rockwell Medical Stock Analysis - MarketRank™

Rockwell Medical scored higher than 80% of companies evaluated by MarketBeat, and ranked 163rd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Rockwell Medical has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rockwell Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rockwell Medical are expected to decrease in the coming year, from $0.03 to ($0.03) per share.

Price to Book Value per Share Ratio

Rockwell Medical has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.59% of the float of Rockwell Medical has been sold short.

Short Interest Ratio / Days to Cover

Rockwell Medical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rockwell Medical has recently increased by 3.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rockwell Medical does not currently pay a dividend.

Dividend Growth

Rockwell Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.35

Percentage of Shares Shorted

0.59% of the float of Rockwell Medical has been sold short.

Short Interest Ratio / Days to Cover

Rockwell Medical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rockwell Medical has recently increased by 3.94%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.22

News Sentiment

Rockwell Medical has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Rockwell Medical this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for RMTI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Rockwell Medical insiders have bought 596.39% more of their company's stock than they have sold. Specifically, they have bought $60,990.00 in company stock and sold $8,758.00 in company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Rockwell Medical is held by insiders.

Percentage Held by Institutions

Only 23.31% of the stock of Rockwell Medical is held by institutions.

RMTI Stock Analysis - Frequently Asked Questions

How have RMTI shares performed this year?

Rockwell Medical's stock was trading at $2.04 at the beginning of 2025. Since then, RMTI stock has decreased by 35.5% and is now trading at $1.3150.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The company earned $18.91 million during the quarter, compared to analyst estimates of $17.46 million. Rockwell Medical had a negative net margin of 0.27% and a negative trailing twelve-month return on equity of 0.90%.
Read the conference call transcript.

When did Rockwell Medical's stock split?

Rockwell Medical shares reverse split before market open on Friday, May 13th 2022.The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

How do I buy shares of Rockwell Medical?

Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rockwell Medical investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Axcelis Technologies (ACLS), Opera (OPRA), ADMA Biologics (ADMA), ASML (ASML) and InterDigital (IDCC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:RMTI
• CIK: 1041024
• Web: www.rockwellmed.com
• Phone: (248) 432-1362
• Fax: 248-960-9119
• Employees: 300
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Rockwell Medical: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +236.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$480 thousand
• Net Margins: -0.27%
• Pretax Margin: -0.27%
• Return on Equity: -0.90%
• Return on Assets: -0.47%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 2.95
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $101.49 million
• Price / Sales: 0.40
• Cash Flow: $0.16 per share
• Price / Cash Flow: 7.37
• Book Value: $1.01 per share
• Price / Book: 1.18

Miscellaneous

• Outstanding Shares: 34,170,000
• Free Float: 32,945,000
• Market Cap: $40.66 million
• Optionable: Optionable
• Beta: 1.57